Market capitalization | $1.03b |
Enterprise Value | $611.32m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 58.22 |
P/S ratio (TTM) P/S ratio | 98.06 |
P/B ratio (TTM) P/B ratio | 1.95 |
Revenue growth (TTM) Revenue growth | 40.22% |
Revenue (TTM) Revenue | $10.50m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
9 Analysts have issued a Autolus Therapeutics plc forecast:
9 Analysts have issued a Autolus Therapeutics plc forecast:
Jun '24 |
+/-
%
|
||
Net Profit | -58 -58 |
28%
28%
|
|
Depreciation and Amortization | 1.90 1.90 |
26%
26%
|
|
Stock Compensation | 2.93 2.93 |
10%
10%
|
|
Operating Cash Flow | -51 -51 |
34%
34%
|
|
Investments | 0.84 0.84 |
81%
81%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -52 -52 |
22%
22%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Christian Itin |
Employees | 463 |
Founded | 2014 |
Website | www.autolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.